Unknown

Dataset Information

0

Safety and Efficacy of Dolutegravir Plus Rilpivirine in Treatment-Experienced HIV-Infected Patients: The DORIVIR Study.


ABSTRACT: OBJECTIVES:To analyze the efficacy and safety of dolutegravir/rilpivirine (DTG/RPV) in HIV-infected patients who switched from any other antiretroviral therapy (ART). METHODS:Open-label, multicenter study including patients who switched to DTG/RPV between February 2015 and February 2016. Efficacy (HIV RNA <50 copies/mL), adverse events, and metabolic changes at 24 weeks were analyzed. RESULTS:A total of 104 participants were included, who switched for the following reasons: toxicity/intolerance (42.3%), convenience (27.8%), and drug interactions (17.3%). Prior regimens are protease inhibitor (56.7%), integrase strand transfer inhibitor (26.9%), and non-nucleoside reverse transcriptase inhibitor (16.3%). Efficacy at 24 weeks was 88.4% (intention to treat) and 96.8% (per protocol). Triglyceride levels were reduced, on average, by 12.7% and a mean decrease of 9.0% in the glomerular filtration rate was observed as well ( P values of .003 and .002, respectively), whereas total cholesterol, HDL cholesterol, LDL cholesterol, creatinine, and glutamic-pyruvic transaminase remained unchanged. No patient discontinued due to adverse events. CONCLUSIONS:Dolutegravir/RPV is effective and safe in long-term HIV-infected patients under any prior ART. Toxicity, convenience, and interactions were the main reasons for changing. At 24 weeks, the lipid profile improved with a decrease in triglycerides.

SUBMITTER: Palacios R 

PROVIDER: S-EPMC6748491 | biostudies-literature | 2018 Jan-Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Safety and Efficacy of Dolutegravir Plus Rilpivirine in Treatment-Experienced HIV-Infected Patients: The DORIVIR Study.

Palacios Rosario R   Mayorga M M   González-Domenech C M CM   Hidalgo-Tenorio C C   Gálvez C C   Muñoz-Medina L L   de la Torre J J   Lozano A A   Castaño M M   Omar M M   Santos Jesús J  

Journal of the International Association of Providers of AIDS Care 20180101


<h4>Objectives</h4>To analyze the efficacy and safety of dolutegravir/rilpivirine (DTG/RPV) in HIV-infected patients who switched from any other antiretroviral therapy (ART).<h4>Methods</h4>Open-label, multicenter study including patients who switched to DTG/RPV between February 2015 and February 2016. Efficacy (HIV RNA <50 copies/mL), adverse events, and metabolic changes at 24 weeks were analyzed.<h4>Results</h4>A total of 104 participants were included, who switched for the following reasons:  ...[more]

Similar Datasets

| S-EPMC4604048 | biostudies-literature
| S-EPMC7243331 | biostudies-literature
| S-EPMC5065232 | biostudies-literature
| S-EPMC5815573 | biostudies-literature
| S-EPMC5916460 | biostudies-literature
| S-EPMC2917795 | biostudies-literature
| S-EPMC5606108 | biostudies-other
| S-EPMC6686958 | biostudies-literature
| S-EPMC6708907 | biostudies-literature
| S-EPMC6336297 | biostudies-literature